Importantly, there are two FDA-approved ICB therapies for breast cancer, the first that came from the Phase III IMpassion130 (NCT02425891) clinical trial that demonstrated atezolizumab in combination with nab-paclitaxel showed significant extension of median disease-free overall survival compared to nab-paclitaxel alone, from 15.5 to 25 months in patients with 1% or more PD-L1-positive immune cells, where there was no benefit in PD-L1 negative tumors [36, 37]. This evidence concerns the gene CD274 and breast carcinoma.